Skip to content

The correlation between clinical profile, metabolic profile, laboratory profile and Fibroscan in MASLD- A real world experience

The correlation between anthropometry, metabolic profile, laboratory profile, non invasive tests and Fibroscan in MASLD- Metabolic Dysfunction Associated Steatotic Liver Disease: A real world experience - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075627
Enrollment
200
Registered
2024-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K768- Other specified diseases of liver

Interventions

Intervention1: nil: nil

Sponsors

nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: •Willingness to give consent and follow up •Fulfilling the criteria for MASLD •Patients with followup records available, with atleast one visit during the study period

Exclusion criteria

Exclusion criteria: •Cirrhosis patients •Decompensated chronic Liver disease •Pregnancy •Chronic viral hepatitis Infections •Hypotension/ shock •History of CAM intake •History of Hepatotoxic drug used in the last 3 months •Alcohol Used disorder

Design outcomes

Primary

MeasureTime frame
1)To compare and correlate Non Invasive test and score – FIB 4/APRI/AST/ALT ratio /NFS with Fibroscan values – CAP /LSM 2)To compare and correlate anthropometry measurements with Fibroscan values – CAP /LSM 3)To compare the non Invasive tests- FIB 4/APRI/AST/ALT ratio /NFS and Fibroscan, pre and post treatment (after 6 months of standrard therapy). Timepoint: 8 months

Secondary

MeasureTime frame
nilTimepoint: nil

Countries

India

Contacts

Public ContactDr Mhasisielie Zumu

Madras Medical Mission Hospital

asizumu@gmail.com9612499310

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026